High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany
- 102 Downloads
Immunomodulatory drugs (IMIDS) have changed the treatment and outcome of patients suffering from multiple myeloma. However, with the oral administration adherence becomes an issue. Since there is no “gold standard” in measuring adherence, we assessed the adherence of myeloma patients with the help of different data sources.
All patients who have been receiving IMIDS for at least 3 months were eligible. Computer assisted personal interviews of patients and, if possible, their caregivers were carried out. Attending oncologists evaluated the patient’s adherence with the help of a standardized questionnaire. In addition, a retrospective analysis of prescription data was conducted. All data were analyzed statistically using SPSS.
One hundred myeloma patients, 35% female, 65% male, with a median age of 70 years (37–86) were interviewed. Prescription data could be evaluated in terms of adherence in 78 patients (78%), 56 caregivers could be questioned (56%). Ninety-seven percent of patients rated themselves as adherent in taking IMIDS. Data from treating oncologists, caregivers and prescriptions supported this result. IMID therapies were rated as very effective and significant, toxicities were acceptable and dosing regimens simple/uncomplicated.
Myeloma patients seem to be highly adherent to IMID treatments.
KeywordsMultiple myeloma Adherence Compliance Immunomodulatory drugs IMIDS Outpatient treatment
Thanks to Vera Friesenhahn and Kristina Kleboth for their support in running this study and to all study nurses who carried out the interviews.
This work was supported through a restricted grant from Celgene GmbH, Germany. Celgene had no role in gathering, analyzing, or interpreting the data.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733–3736. https://doi.org/10.1182/blood-2010-10-309807 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388. https://doi.org/10.1200/jco.2009.26.3087 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS (2006) Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 44(5):471–477. https://doi.org/10.1097/01.mlr.0000207817.32496.cb CrossRefPubMedGoogle Scholar
- 20.Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, Coolbrandt A, Biganzoli L (2017) Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev 57:58–66. https://doi.org/10.1016/j.ctrv.2017.05.002 CrossRefPubMedGoogle Scholar
- 22.Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J (2004) How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 13(1):11–19. https://doi.org/10.1002/pds.819 CrossRefPubMedGoogle Scholar
- 26.Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, Koppler H, van Roye C, Thomalla J (2016) Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice. SpringerPlus 5:270. https://doi.org/10.1186/s40064-016-1851-z CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Annals of oncology: official journal of the European society for. Med Oncol 20(3):431–436. https://doi.org/10.1093/annonc/mdn646 CrossRefGoogle Scholar
- 33.Timmers L, Boons CC, Moes-Ten Hove J, Smit EF, van de Ven PM, Aerts JG, Swart EL, Boven E, Hugtenburg JG (2015) Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol 141(8):1481–1491. https://doi.org/10.1007/s00432-015-1935-0 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Arber A, Odelius A, Williams P, Lemanska A, Faithfull S (2017) Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study. Eur J Cancer Care 26(2). https://doi.org/10.1111/ecc.12413
- 35.Timmers L, Boons CC, Kropff F, van de Ven PM, Swart EL, Smit EF, Zweegman S, Kroep JR, Timmer-Bonte JN, Boven E, Hugtenburg JG (2014) Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol (Stockh) 53(2):259–267. https://doi.org/10.3109/0284186x.2013.844353 CrossRefGoogle Scholar
- 37.Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U (2011) Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 19(7):1009–1018. https://doi.org/10.1007/s00520-010-0927-5 CrossRefPubMedGoogle Scholar
- 39.Chari A, Bhor M, Eldjerou L, Gilligan AM, Urniasz A, Globe D, Stetsovsky D, Varker H, Davis B, Bonafede M, Talcott J (2018) Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. Future Oncol. https://doi.org/10.2217/fon-2017-0727
- 40.Cransac ASB, Marty-Quinternet S, Pernot C, Caillot D, Boulin M (2017) DI-053 adherence to immunomodulatory drugs in patients with multiple myeloma. Eur J Hosp Pharm 24:A136–A137Google Scholar